Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Bill Payers, Doctors in Skirmish over Drug Price Survey for Gap-Year Revisions: Chuikyo
February 9, 2017
- Chuikyo OKs Optimal Use Guidelines for Opdivo and Keytruda, Due Out Feb. 14
February 9, 2017
- PMDA to Delay Planned Staff Increase for Financial Reasons, Pace of Increase Has Slowed Down
February 9, 2017
- Keytruda Gets Same Daily Price as Opdivo; Chuikyo OKs Batch of Drugs for Feb. 15 Listing
February 8, 2017
- MHLW Notifies of Package Insert Changes for Iguratimod
February 8, 2017
- Sanofi’s VEGF Inhibitor Clears MHLW Advisory Panel for Colorectal Cancer
February 6, 2017
- MHLW Will Strictly Respond to Violations, Shiozaki Says on Fake Harvoni Issue
February 6, 2017
- MHLW Wraps Up Probe into Fake Harvoni after Distribution Routes “Most Likely” Identified
February 2, 2017
- MHLW to Set Up Committee on Pharmaceutical and Medical Device Regulation at Health Sciences Council
February 2, 2017
- MHLW to Actively Recommend Japanese Encephalitis Vaccine for Children Turning 18
February 2, 2017
- MHLW Pins Down Distribution Routes for Harvoni Counterfeits; Composition of Fake Pills Identified
February 1, 2017
- MHLW, Pharma Industry Officials Agree on Conditional Early Approval System
January 31, 2017
- Shiozaki Calls for Enactment of Clinical Research Bill ASAP
January 30, 2017
- MHLW Committee to Discuss Shionogi’s OIC Drug on Feb. 9
January 27, 2017
- Govt’s Bleak Primary Deficit Outlook to Weigh Further on Social Securities
January 26, 2017
- AMED to Collaborate with UK Funding Agency, Open London Office
January 26, 2017
- MHLW Lays Out Chuikyo Discussion Timeline for Drug Pricing Overhaul
January 26, 2017
- Industry Wants Simplified Rule, Limited Application for Foreign Price Adjustment: Chuikyo
January 26, 2017
- Chuikyo on Alert for Trump’s Possible Pressure on Drug Front
January 26, 2017
- MHLW Warns Against Purchasing Harvoni in Unpackaged Bottles
January 26, 2017
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…